AGM
XBIT icon

Alpine Global Management’s XBiotech XBIT Stock Holding History

Alpine Global Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,809
Closed -$91.5K – 481
2024
Q2 		$91.5K Buy
+17,809
New +$137K 0.02% 421

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Alpine Global Management's XBIT Position: Q3 2024 in Review

Alpine Global Management sold out of XBiotech (XBIT) in Q3 2024, closing a stake of 17,809 shares — an estimated $91.5K sold.

Alpine Global Management first reported a position in XBIT in Q2 2024 and held it in 1 quarter. The position peaked at $91.5K in Q2 2024. 50 funds tracked by Wall St. Rank hold XBIT as of Q3 2024.

  • Alpine Global Management reported no remaining XBiotech position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 17,809 XBiotech shares in Q3 2024, an estimated $91.5K.
  • Alpine Global Management first reported a position in XBiotech in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's XBiotech position peaked at $91.5K in Q2 2024.
  • 50 funds tracked by Wall St. Rank held XBiotech as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.